Business Context and Reporting Period
Company: Renovaro Inc. (Note: Request metadata referenced "Lunai Bioworks Inc.", but the filing text identifies the registrant as Renovaro Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: February 26, 2025
Event: Entry into a Material Definitive Agreement (Merger Agreement) with Biosymetrics, Inc., a company focused on artificial intelligence-driven drug discovery and biomarker identification.
Key Financial Metrics
This filing is a Current Report regarding a corporate transaction and does not contain periodic financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Transaction Consideration: Renovaro will issue 15 million shares of its common stock to Biosymetrics stockholders upon closing.
Material Changes and Transaction Terms
- Structure: Renovaro Acquisition Sub (a wholly-owned subsidiary of Renovaro) will merge with and into Biosymetrics, with Biosymetrics surviving as a wholly-owned subsidiary of Renovaro.
- Share Issuance: 15 million shares of Renovaro common stock will be issued to Biosymetrics stockholders.
- Lock-Up and Escrow:
- The CEO and majority stockholder of Biosymetrics is subject to a one-year lock-up on shares received.
- 3 million of the issued shares must be held in escrow for one year post-closing to secure indemnification obligations.
- Registration Status: The shares are unregistered under Section 4(a)(2) of the Securities Act and will not be freely tradable immediately upon closing.
Guidance, Outlook, Risks, and Contingencies
Closing Conditions: The transaction is subject to customary conditions, including Biosymetrics stockholder approval, Nasdaq listing of the shares, and accuracy of representations and warranties.
Termination Rights: Either party may terminate the agreement if:
- The transaction does not close by March 15, 2025.
- Biosymetrics stockholders do not approve the transaction.
- A governmental authority issues an order prohibiting the transaction.
Risks and Uncertainties:
- There is no assurance the Merger Agreement will close or the timing of such closing.
- Non-accredited investors among Biosymetrics stockholders will receive a cash payment equivalent to the value of shares they would otherwise receive.
- Representations and warranties in the agreement are for the benefit of the parties and should not be relied upon as characterizations of actual facts by security holders.
Investor Verification Checklist
- Verify the final closing date, as the agreement allows for termination if not closed by March 15, 2025.
- Confirm the outcome of the Biosymetrics stockholder vote required for closing.
- Monitor the Nasdaq listing approval status for the 15 million new shares.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific indemnification triggers affecting the 3 million escrowed shares.
- Check for any subsequent press releases or filings regarding the transaction status, as Renovaro stated it does not intend to discuss further developments unless required by law.